We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+30.91%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.29B
AUM Growth
+$94.4M
Cap. Flow
-$78.5M
Cap. Flow %
-6.1%
Top 10 Hldgs %
48.93%
Holding
207
New
56
Increased
31
Reduced
35
Closed
51

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$30.6M
2
QURE icon
uniQure
QURE
+$18.4M
3
NVRO
NEVRO CORP.
NVRO
+$16.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$12.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$12M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$34.8M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$21.8M
3
ESPR
Esperion Therapeutics
ESPR
+$19.5M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$19.3M
5
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 84.11%
2 Miscellaneous 14.93%
3 Consumer Staples 0.85%
4 Technology 0.05%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
151
CALL
MannKind Corp
MNKD
$1.14B
$1K ﹤0.01%
+20
New +$603
PRPO icon
152
Precipio
PRPO
$48.6M
– –
-14
Closed -$272K
AVDL
153
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-644,111
Closed -$3.68M
BDX icon
154
Becton Dickinson
BDX
$50.6B
– –
-82,000
Closed -$11.1M
CLDX icon
155
Celldex Therapeutics
CLDX
$3.02B
– –
-6,667
Closed -$1.82M
CNC icon
156
Centene
CNC
$33.4B
– –
-9,936
Closed -$258K
DBVT
157
DBV Technologies
DBVT
$739M
– –
-11,262
Closed -$2.67M
HRTX icon
158
Heron Therapeutics
HRTX
$59.6M
– –
-666,042
Closed -$6.7M
LRMR icon
159
Larimar Therapeutics
LRMR
$406M
– –
-23,193
Closed -$8.58M
MNKD icon
160
PUT
MannKind Corp
MNKD
$1.14B
– –
-40,000
Closed -$1.04M
NBIX icon
161
PUT
Neurocrine Biosciences
NBIX
$15.2B
– –
-1,600,000
Closed -$35.7M
PRQR icon
162
ProQR Therapeutics
PRQR
$260M
– –
-100,000
Closed -$2.17M
PRTA icon
163
Prothena Corp
PRTA
$428M
– –
-247,336
Closed -$5.13M
PTCT icon
164
PTC Therapeutics
PTCT
$5.48B
– –
-671,736
Closed -$34.8M
QDEL icon
165
QuidelOrtho
QDEL
$729M
– –
-142,500
Closed -$4.12M
SEM
166
DELISTED
Select Medical
SEM
– –
-24,805
Closed -$192K
SNN icon
167
Smith & Nephew
SNN
$11.7B
– –
-67,407
Closed -$2.48M
SUPN icon
168
Supernus Pharmaceuticals
SUPN
$2.4B
– –
-22,285
Closed -$185K
USPH icon
169
US Physical Therapy
USPH
$1.22B
– –
-5,156
Closed -$216K
VRTX icon
170
Vertex Pharmaceuticals
VRTX
$130B
– –
-110,000
Closed -$13.1M
VRTX icon
171
PUT
Vertex Pharmaceuticals
VRTX
$130B
– –
-100,000
Closed -$11.9M
XOMA
172
CALL
DELISTED
Xoma
XOMA
– –
-10
Closed -$1K
NBSE
173
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-15
Closed -$50K
SIEN
174
DELISTED
Sientra, Inc.
SIEN
– –
-3,700
Closed -$621K
SGEN
175
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-900
Closed -$29K
4 5 6
7
8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Perceptive Advisors held 207 positions worth $1.29B, up 7.9% from $1.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Perceptive Advisors withdrew a net $78.5M in Q1 2015, closing 51 positions and reducing 35 holdings. Its most notable exit was PTC Therapeutics, an estimated $34.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Iovance Biotherapeutics worth $32.9M.

  • Perceptive Advisors's largest Q1 2015 buy was Iovance Biotherapeutics: 2,714,549 shares worth $32.9M.
  • Perceptive Advisors added most to uniQure in Q1 2015, an estimated $18.4M increase.
  • Perceptive Advisors's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $21.8M.
  • Perceptive Advisors fully exited PTC Therapeutics in Q1 2015, selling an estimated $34.8M.
  • Perceptive Advisors's ten largest holdings make up 49% of its $1.29B portfolio in Q1 2015.
  • Perceptive Advisors opened 56 new positions and closed 51 in Q1 2015.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $1.29B.

Based on Perceptive Advisors's 13F filing for Q1 2015, filed 15 May 2015.